Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphisms

Abstract

Patients carrying the CYP3A*1B allele may have enhanced docetaxel clearance and may be underexposed, whereas those carrying GSTP1*A/*B and 3435TT genotypes may have excessive hematologic toxicity. Further studies are warranted to determine the usefulness of genotyping before docetaxel treatment.